Kiora Pharmaceuticals Inc. (KPRX)
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026
Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
Veteran Investor and Widely Followed Market Analyst Shah Gilani Calls VENU Stock “Significantly Undervalued”
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
MarketAxess Introduces TraX Tape, Delivering an Enriched View of Bond Market Activity
Oklo, Centrus Sign Letter of Intent to Purchase Nuclear Fuel for Aurora Powerhouse Deployment in Southern Ohio
Enhanced Closes Initial Tranche of $50 Million Financing
Bitdeer Announces May 2026 Production and Operations Update